Jiwei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jiwei Zhang has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Li Feng
Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China
6 shared publicationsChao Wu
Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China
5 shared publicationsLiting Wei
Department of Neurology, Luoyang Central Hospital, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, China
5 shared publicationsDingbang Chen
Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China
4 shared publicationsRui Wang
Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong 510530, China
4 shared publicationsXunhua Li
Department of Neurology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, Guangdong, China
3 shared publications
Latest Publications
- Open Access
- 13 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Post-COVID-19 surge in Guillain-Barré syndrome during the Omicron wave in China with clinical characteristics and potential immune-mediated pathways
This multicenter study investigated the epidemiological and clinical characteristics of Guillain-Barré syndrome (GBS) during China’s Omicron wave (December 2022–February 2023), and compared the number of GBS hospitalizations with the historical data for the same period from 2018 to 2022. A retrospective analysis was conducted at two tertiary hospitals, categorizing patients into COVID-GBS (case group) and Non-COVID-GBS (control group). During the Omicron wave, the number of GBS hospitalizations was 1.5 times higher compared to the period of 2018–2019 (99 cases vs. 66 cases). Poisson regression analysis confirmed a significant increase in GBS incidence during the Omicron wave (December 2022–February 2023) compared to the 2018–2019 baseline period, with an IRR of 1.541 (95% CI: 1.123–2.129, p = 0.0079). COVID-19-associated GBS patients were significantly older (54.04 vs. 42.06 years, p = 0.002) and exhibited higher rates of cranial nerve involvement ( p = 0.014), particularly bulbar involvement ( p = 0.009). Acute severity was greater in COVID-19-associated cases, evidenced by elevated ICU admissions, higher peak GBS disability scores ( p = 0.048), increased mechanical ventilation needs, and one fatality. The median latency from COVID-19 infection to neurological onset was 9.5 days (IQR: 8–14). Despite these acute differences, 6-month disability outcomes showed no significant divergence between groups, suggesting similar long-term prognoses. The surge in GBS incidence aligns with broader reports of elevated GBS rates during COVID-19 surges, though mechanistic links may involve immune-mediated pathways rather than direct viral causation.
- 13 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessPost-COVID-19 surge in Guillain-Barré syndrome during the Omicron wave in China with clinical characteristics and potential immune-mediated pathways
This multicenter study investigated the epidemiological and clinical characteristics of Guillain-Barré syndrome (GBS) during China’s Omicron wave (December 2022–February 2023), and compared the number of GBS hospitalizations with the historical data for the same period from 2018 to 2022. A retrospective analysis was conducted at two tertiary hospitals, categorizing patients into COVID-GBS (case group) and Non-COVID-GBS (control group). During the Omicron wave, the number of GBS hospitalizations was 1.5 times higher compared to the period of 2018–2019 (99 cases vs. 66 cases). Poisson regression analysis confirmed a significant increase in GBS incidence during the Omicron wave (December 2022–February 2023) compared to the 2018–2019 baseline period, with an IRR of 1.541 (95% CI: 1.123–2.129, p = 0.0079). COVID-19-associated GBS patients were significantly older (54.04 vs. 42.06 years, p = 0.002) and exhibited higher rates of cranial nerve involvement ( p = 0.014), particularly bulbar involvement ( p = 0.009). Acute severity was greater in COVID-19-associated cases, evidenced by elevated ICU admissions, higher peak GBS disability scores ( p = 0.048), increased mechanical ventilation needs, and one fatality. The median latency from COVID-19 infection to neurological onset was 9.5 days (IQR: 8–14). Despite these acute differences, 6-month disability outcomes showed no significant divergence between groups, suggesting similar long-term prognoses. The surge in GBS incidence aligns with broader reports of elevated GBS rates during COVID-19 surges, though mechanistic links may involve immune-mediated pathways rather than direct viral causation.
- Open Access
- 25 April 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1345953
Clinical characteristics of patients with autoimmune nodopathy with anti-neurofascin155 antibodies
Background: According to the latest guidelines on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), patients with CIDP with anti-neurofascin 155 (NF155) antibodies are referred to as autoimmune nodopathy (AN), an autoimmune disorder distinct from CIDP. We aimed to compare the clinical data of patients with AN with anti-NF155 antibodies with those of anti-NF155 antibodies-negative patients with CIDP, and to summarize the clinical characteristics of patients with AN with anti-NF155 antibodies.Methods: Nine patients with AN with anti-NF155 antibodies and 28 serologically negative patients with CIDP were included in this study. Diagnosis was made according to the diagnostic criteria in the European Academy of Neurology (EAN)/Peripheral Nerve Society (PNS) guidelines on CIDP published in 2021. Demographics, clinical manifestations, electrophysiological examination, cerebrospinal fluid (CSF) tests, and response to treatment were retrospectively analyzed.Results: Compared with serologically negative patients with CIDP, those patients with AN with anti-NF155 antibodies were younger (p=0.007), had a younger onset age (p=0.009), more frequent ataxia (p=0.019), higher CSF protein levels (p=0.001), and more frequent axon damage in electrophysiology (p=0.025). The main characteristics of patients with AN with anti-NF155 antibodies include younger age and onset age, limb weakness, sensory disturbance, ataxia, multiple motor−sensory peripheral neuropathies with demyelination and axonal damage on electrophysiological examination, markedly elevated CSF protein levels, and varying degrees of response to immunotherapy.Conclusions: Patients with AN with anti-NF155 antibodies differed from serologically negative patients with CIDP in terms of clinical characteristics. When AN is suspected, testing for antibodies associated with the nodes of Ranvier is essential for early diagnosis and to guide treatment.
- 25 April 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1345953
Open AccessClinical characteristics of patients with autoimmune nodopathy with anti-neurofascin155 antibodies
Background: According to the latest guidelines on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), patients with CIDP with anti-neurofascin 155 (NF155) antibodies are referred to as autoimmune nodopathy (AN), an autoimmune disorder distinct from CIDP. We aimed to compare the clinical data of patients with AN with anti-NF155 antibodies with those of anti-NF155 antibodies-negative patients with CIDP, and to summarize the clinical characteristics of patients with AN with anti-NF155 antibodies.Methods: Nine patients with AN with anti-NF155 antibodies and 28 serologically negative patients with CIDP were included in this study. Diagnosis was made according to the diagnostic criteria in the European Academy of Neurology (EAN)/Peripheral Nerve Society (PNS) guidelines on CIDP published in 2021. Demographics, clinical manifestations, electrophysiological examination, cerebrospinal fluid (CSF) tests, and response to treatment were retrospectively analyzed.Results: Compared with serologically negative patients with CIDP, those patients with AN with anti-NF155 antibodies were younger (p=0.007), had a younger onset age (p=0.009), more frequent ataxia (p=0.019), higher CSF protein levels (p=0.001), and more frequent axon damage in electrophysiology (p=0.025). The main characteristics of patients with AN with anti-NF155 antibodies include younger age and onset age, limb weakness, sensory disturbance, ataxia, multiple motor−sensory peripheral neuropathies with demyelination and axonal damage on electrophysiological examination, markedly elevated CSF protein levels, and varying degrees of response to immunotherapy.Conclusions: Patients with AN with anti-NF155 antibodies differed from serologically negative patients with CIDP in terms of clinical characteristics. When AN is suspected, testing for antibodies associated with the nodes of Ranvier is essential for early diagnosis and to guide treatment.
- 14 March 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 45 (8) , 3817-3822
Essential tremor is associated with reduced serum ceruloplasmin levels
Background Essential tremor (ET), a prevalent movement disorder, has an elusive pathogenesis. A reduction in ceruloplasmin (Cp) levels can be found in some patients with ET. In addition, some studies have suggested an association between ET and neurodegeneration. As a ferroxidase, Cp is critical for iron metabolism, protecting against oxidative stress and neurodegeneration. Iron metabolism dysregulation, linked to ferroptosis, has implications in neurodegenerative diseases. Yet, research on Cp and ET remains limited. Objectives This study aims to elucidate the relationship between ET and serum Cp levels. Methods We collected demographic and clinical data from 62 patients with ET satisfying the diagnostic criteria and compared these to data from 100 healthy controls. Results The median Cp levels in ET patients were 21.5 (18.8, 23.9) mg/dL, significantly lower than those in controls (23.1 [(20.7, 25.7) mg/dL; P = 0.006]). A reduction in Cp levels emerged as a risk factor for ET incidence (odds ratio (OR) = 0.873, 95% confidence interval (CI), 0.795, 0.959; P = 0.005). The area under the receiver operating characteristic (ROC) curve for serum Cp levels to predict the onset of ET was 0.629 (95% CI, 0.537–0.720; P = 0.006), and the optimal cut-off value for Cp levels was 19.5 mg/dL with a sensitivity of 91% and a specificity of 33.9%. Conclusion Our analysis suggests that reduced Cp levels are associated with ET. We speculate that reduced Cp levels may be involved in the pathogenesis of ET, which requires further studies.
- 14 March 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 45 (8) , 3817-3822
Essential tremor is associated with reduced serum ceruloplasmin levels
Background Essential tremor (ET), a prevalent movement disorder, has an elusive pathogenesis. A reduction in ceruloplasmin (Cp) levels can be found in some patients with ET. In addition, some studies have suggested an association between ET and neurodegeneration. As a ferroxidase, Cp is critical for iron metabolism, protecting against oxidative stress and neurodegeneration. Iron metabolism dysregulation, linked to ferroptosis, has implications in neurodegenerative diseases. Yet, research on Cp and ET remains limited. Objectives This study aims to elucidate the relationship between ET and serum Cp levels. Methods We collected demographic and clinical data from 62 patients with ET satisfying the diagnostic criteria and compared these to data from 100 healthy controls. Results The median Cp levels in ET patients were 21.5 (18.8, 23.9) mg/dL, significantly lower than those in controls (23.1 [(20.7, 25.7) mg/dL; P = 0.006]). A reduction in Cp levels emerged as a risk factor for ET incidence (odds ratio (OR) = 0.873, 95% confidence interval (CI), 0.795, 0.959; P = 0.005). The area under the receiver operating characteristic (ROC) curve for serum Cp levels to predict the onset of ET was 0.629 (95% CI, 0.537–0.720; P = 0.006), and the optimal cut-off value for Cp levels was 19.5 mg/dL with a sensitivity of 91% and a specificity of 33.9%. Conclusion Our analysis suggests that reduced Cp levels are associated with ET. We speculate that reduced Cp levels may be involved in the pathogenesis of ET, which requires further studies.
- 5 March 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (3) , e28609
Sulforaphane is a reversible covalent inhibitor of 3‐chymotrypsin‐like protease of SARS‐CoV‐2
The ongoing pandemic of coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has posed a major public health threat worldwide and emphasizes an urgent need for effective therapeutics. Recently, Ordonez et al. identified sulforaphane (SFN) as a novel coronavirus inhibitor both in vitro and in mice, but the mechanism of action remains elusive. In this study, we independently discovered SFN for its inhibitory effect against SARS‐CoV‐2 using a target‐based screening approach, identifying the viral 3‐chymotrypsin‐like protease (3CLpro) as a target of SFN. Mechanistically, SFN inhibits 3CLpro in a reversible, mixed‐type manner. Moreover, enzymatic kinetics studies reveal that SFN is a slow‐binding inhibitor, following a two‐step interaction. Initially, an encounter complex forms by specific binding of SFN to the active pocket of 3CLpro; subsequently, the isothiocyanate group of SFN as “warhead” reacts covalently to the catalytic cysteine in a slower velocity, stabilizing the SFN‐3CLpro complex. Our study has identified a new lead of the covalent 3CLpro inhibitors which has potential to be developed as a therapeutic agent to treat SARS‐CoV‐2 infection.
- 5 March 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (3) , e28609
Sulforaphane is a reversible covalent inhibitor of 3‐chymotrypsin‐like protease of SARS‐CoV‐2
The ongoing pandemic of coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has posed a major public health threat worldwide and emphasizes an urgent need for effective therapeutics. Recently, Ordonez et al. identified sulforaphane (SFN) as a novel coronavirus inhibitor both in vitro and in mice, but the mechanism of action remains elusive. In this study, we independently discovered SFN for its inhibitory effect against SARS‐CoV‐2 using a target‐based screening approach, identifying the viral 3‐chymotrypsin‐like protease (3CLpro) as a target of SFN. Mechanistically, SFN inhibits 3CLpro in a reversible, mixed‐type manner. Moreover, enzymatic kinetics studies reveal that SFN is a slow‐binding inhibitor, following a two‐step interaction. Initially, an encounter complex forms by specific binding of SFN to the active pocket of 3CLpro; subsequently, the isothiocyanate group of SFN as “warhead” reacts covalently to the catalytic cysteine in a slower velocity, stabilizing the SFN‐3CLpro complex. Our study has identified a new lead of the covalent 3CLpro inhibitors which has potential to be developed as a therapeutic agent to treat SARS‐CoV‐2 infection.
- Open Access
- 15 April 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (15) , eabk2376
Mitolysosome exocytosis, a mitophagy-independent mitochondrial quality control in flunarizine-induced parkinsonism-like symptoms
Mitochondrial quality control plays an important role in maintaining mitochondrial homeostasis and function. Disruption of mitochondrial quality control degrades brain function. We found that flunarizine (FNZ), a drug whose chronic use causes parkinsonism, led to a parkinsonism-like motor dysfunction in mice. FNZ induced mitochondrial dysfunction and decreased mitochondrial mass specifically in the brain. FNZ decreased mitochondrial content in both neurons and astrocytes, without affecting the number of nigral dopaminergic neurons. In human neural progenitor cells, FNZ also induced mitochondrial depletion. Mechanistically, independent of ATG5- or RAB9-mediated mitophagy, mitochondria were engulfed by lysosomes, followed by a vesicle-associated membrane protein 2– and syntaxin-4–dependent extracellular secretion. A genome-wide CRISPR knockout screen identified genes required for FNZ-induced mitochondrial elimination. These results reveal not only a previously unidentified lysosome-associated exocytosis process of mitochondrial quality control that may participate in the FNZ-induced parkinsonism but also a drug-based method for generating mitochondria-depleted mammal cells.
- 15 April 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (15) , eabk2376
Open AccessMitolysosome exocytosis, a mitophagy-independent mitochondrial quality control in flunarizine-induced parkinsonism-like symptoms
Mitochondrial quality control plays an important role in maintaining mitochondrial homeostasis and function. Disruption of mitochondrial quality control degrades brain function. We found that flunarizine (FNZ), a drug whose chronic use causes parkinsonism, led to a parkinsonism-like motor dysfunction in mice. FNZ induced mitochondrial dysfunction and decreased mitochondrial mass specifically in the brain. FNZ decreased mitochondrial content in both neurons and astrocytes, without affecting the number of nigral dopaminergic neurons. In human neural progenitor cells, FNZ also induced mitochondrial depletion. Mechanistically, independent of ATG5- or RAB9-mediated mitophagy, mitochondria were engulfed by lysosomes, followed by a vesicle-associated membrane protein 2– and syntaxin-4–dependent extracellular secretion. A genome-wide CRISPR knockout screen identified genes required for FNZ-induced mitochondrial elimination. These results reveal not only a previously unidentified lysosome-associated exocytosis process of mitochondrial quality control that may participate in the FNZ-induced parkinsonism but also a drug-based method for generating mitochondria-depleted mammal cells.
- Open Access
- 1 August 2020
- Published by Elsevier in Stem Cell Research
- Vol. 47, 101909
Generation of an integration-free induced pluripotent stem cell (iPSC) line (ZZUNEUi005-A) from a Wilson's disease patient harboring a homozygous Pro992Leu mutation in ATP7B gene
- 1 August 2020
- Published by Elsevier in Stem Cell Research
- Vol. 47, 101909
Open AccessGeneration of an integration-free induced pluripotent stem cell (iPSC) line (ZZUNEUi005-A) from a Wilson's disease patient harboring a homozygous Pro992Leu mutation in ATP7B gene
- Open Access
- 1 May 2020
- Published by Elsevier in Stem Cell Research
- Vol. 45, 101809
Generation of an integration-free induced pluripotent stem cell (iPSC) line (ZZUNEUi001-A) from a healthy male individual
- 1 May 2020
- Published by Elsevier in Stem Cell Research
- Vol. 45, 101809
Open AccessGeneration of an integration-free induced pluripotent stem cell (iPSC) line (ZZUNEUi001-A) from a healthy male individual
- Open Access
- 1 April 2020
- Published by Elsevier in Stem Cell Research
- Vol. 44, 101741
Generation of an integration-free induced pluripotent stem cell (iPSC) line (ZZUNEUi004-A) from a Wilson's disease patient harboring a homozygous Pro992Leu mutation in ATP7B gene
- 1 April 2020
- Published by Elsevier in Stem Cell Research
- Vol. 44, 101741
Open AccessGeneration of an integration-free induced pluripotent stem cell (iPSC) line (ZZUNEUi004-A) from a Wilson's disease patient harboring a homozygous Pro992Leu mutation in ATP7B gene
- Open Access
- 1 December 2019
- Published by Elsevier in Stem Cell Research
- Vol. 41, 101664
Generation of an integration-free induced pluripotent stem cell (iPSC) line (ZZUNEUi003-A) from a Wilson's disease patient harboring a homozygous R778L mutation in ATP7B gene
- 1 December 2019
- Published by Elsevier in Stem Cell Research
- Vol. 41, 101664
Open AccessGeneration of an integration-free induced pluripotent stem cell (iPSC) line (ZZUNEUi003-A) from a Wilson's disease patient harboring a homozygous R778L mutation in ATP7B gene
- 1 January 2018
- Published by Elsevier in Neuroscience Letters
- Vol. 664, 107-109
Novel, de novo dysferlin gene mutations in a patient with Miyoshi myopathy
- 1 January 2018
- Published by Elsevier in Neuroscience Letters
- Vol. 664, 107-109
Novel, de novo dysferlin gene mutations in a patient with Miyoshi myopathy